The primary objectives of the biostatistics as core resource in the GI Cancer SPORE are proper design of studies, ongoing monitoring, ensuring data quality and completeness in ongoing studies, state-of-the-art statistical analyses of results, and assistance to investigators in interpreting and presenting result. The guiding philosophy will be to keep quantitative aspects of the research closely tied to the specific aims, and to have the collaboration of the investigator and biostatistician such that the biologic knowledge of the researcher plays an integral part in shaping the statistical analyses. To achieve these objectives, the core biostatistician will be available to SPORE investigators at all phases of their projects. Discussion of study aims, appropriate design parameters (i.e. study structure and sample size), interim analyses, analytical plans, interpretation of results and guidance for publication will be provided as needed. All analyses will use the most current methods and will be conducted or supervised by the statistician. Because many of these analyses are exploratory and are meant to assess new methods, there will be emphasis on estimation of important clinics and laboratory parameters with confidence intervals and likelihood/Bayesian methodology rather than statistical, hypothesis testing. The core statistician has experience in a number of areas of particular value to core investigators; inference in situations where there is relatively little empirical data, analysis of clinical research with small numbers of subjects, gene expression in GI tumors, and evaluation of cancer screening tests. He will be assisted by an experienced member of the Oncology/Biostatistics staff, who will have the responsibility for performing most of the statistical analyses under his supervision.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA062924-08S1
Application #
6496916
Study Section
Project Start
2001-05-04
Project End
2002-06-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205

Showing the most recent 10 out of 883 publications